FluGen, Inc. announces the initiation of the first study in older adults of M2SR, the company's investigational supra-seasonal, live, single-replication, intranasal influenza vaccine.
Find more companies like FluGen
Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.